SCHEMBL4733727

SCHEMBL4733727

Cc1noc2ncnc(Cl)c12

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.55
ALDH1A1 P00352 6/20 0.55
LMNA P02545 5/20 0.55
HTT P42858 4/20 0.55
NPSR1 Q6W5P4 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.51
GFER P55789 1/20 0.50
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784582 0.76 ALDH1A1 (0.51) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL9602045 0.74 MAPT (0.61) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL13064192 0.73 POLB (0.57) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL14088821 0.73 POLB (0.66) MAPTALDH1A1LMNAHTTMEN1
SCHEMBL31285809 0.69 IDO1 (0.47) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL31714740 0.69 IDO1 (0.47) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL4782884 0.69 IDO1 (0.47) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL22407290 0.68 KDR (0.53) ALDH1A1LMNANPSR1MEN1KMT2A
SCHEMBL439175 0.68 NOTUM (0.46) MAPTALDH1A1LMNAHTTNPSR1
SCHEMBL3706204 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250017935-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY 2025-01-16 US disclosed
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof HAIHE BIOPHARMA CO., LTD. (CN) 2024-11-21 US disclosed
EP-4400493-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2024-07-17 EP disclosed
CN-115232117-B Substituted isoxazole pyrimidine amine compound, preparation method and application thereof 沈阳中化农药化工研发有限公司 2024-07-16 CN disclosed
CN-117980293-A Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof 上海海和药物研究开发股份有限公司 2024-05-03 CN disclosed
WO-2023064587-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY (US) 2023-04-20 WO disclosed
CN-110964037-B Pyrimidine-fused ring-containing compound and preparation method and application thereof 沈阳中化农药化工研发有限公司 2023-03-28 CN disclosed
WO-2023036289-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-03-16 WO disclosed
CN-115232117-A Substituted isoxazole pyrimidinamine compound and preparation method and application thereof 沈阳中化农药化工研发有限公司 2022-10-25 CN disclosed
CN-108069984-B Substituted five-membered heterocyclic compound containing pyrimido ring and preparation method and application thereof 沈阳中化农药化工研发有限公司 2021-02-05 CN disclosed
CN-108069973-B Substituted six-membered heterocyclic compound containing pyrimido ring and preparation method and application thereof 沈阳中化农药化工研发有限公司 2020-08-11 CN disclosed
CN-110964037-A Pyrimidine-fused ring-containing compound and preparation method and application thereof 沈阳中化农药化工研发有限公司 2020-04-07 CN disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
WO-2008057402-A2 N-ARYL-ISOXAZOLOPYRIMIDIN-4-AMINES AND RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2008-05-15 WO disclosed
WO-2008057402-A2 N-ARYL-ISOXAZOLOPYRIMIDIN-4-AMINES AND RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2008-05-15 WO disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof ENPP1, ENPP2, ENPP3 MAPT 4109/4885ALDH1A1 1990/4885LMNA 2698/4885
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP MAPT 208/4885ALDH1A1 376/4885LMNA 1955/4885
US-20250017935-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS CHRM5, CHRM4, CHRM1 MAPT 745/4885ALDH1A1 1765/4885LMNA 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.